Dr Oscar Cumming has extensive research experience, working as a Principal Investigator at Novatrials since 2020 in clinical trials as listed below.

Principal Investigator

  • Phase 3 study to evaluate the efficacy, safety and tolerability of maridebart cafraglutide in participants without type 2 diabetes mellitus who have obesity or overweight

  • Phase 1 study evaluating the safety and efficacy of LMN-0801 for weight loss

  • Phase 3 study to evaluate the treatment effect of pentosan polysulfate sodium compared to placebo in participants with knee osteoarthritis pain

  • Phase 2 Study to Assess BHV-1300 in Participants with Graves’ Disease

  • Phase 3 cardiovascular safety study with BI456906 compared with placebo in participants with overweight or obesity with established cardiovascular disease or chronic kidney disease, or at least two risk factors for CVD.

  • Phase 2 study to evaluate the safety and efficacy of CPX101 in overweight and obese subjects without diabetes mellitus

  • Phase 1a study to evaluate the safety of CYT-108 for the therapy of mild to moderate primary osteoarthritis of the knee 

  • Phase 2b study to evaluate efficacy and safety of HB-1 for panic disorder

  • Phase 1-2 study of IG3018 to evaluate the safety, tolerability ,efficacy and pharmacokinetics in subjects with hyperuricemia with or without chronic kidney disease

  • Phase 3 study to evaluate the efficacy and safety of Milvexian, an oral factor XIa Inhibitor versus Apixaban in participants with Atrial Fibrillation.

  • Phase 2 study to determine the safety and efficacy on pain and function according to RAPID-3 of IHL-675A in patients with Rheumatoid Arthritis.

  • Phase 2 study to evaluate the efficacy and safety of GSK3858279 in adults with knee Osteoarthritis pain.

  • Phase 1 study to evaluate the pharmacokinetics, safety and preliminary efficacy of two strengths of DARE-PDM1 (1%or3%) versus placebo among women with symptomatic primary Dysmenorrhea.

  • Phase 1b/2 study to evaluate the safety and efficacy of a single dose of LG00034053 administered by intra-articular injection in patients with knee Osteoarthritis.

  • Phase 3a study to evaluate efficacy and safety of cagrilintide 2.4mg in combination with semaglutide 2.4mg (CagriSema 2.4mg/2.4mg) once weekly in participants with Overweight or Obesity

  • Phase 3a study to evaluate the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti-diabetic drugs, in participants with Type 2 Diabetes inadequately controlled with daily basal insulin.

  • Phase 2 study of the safety and immunogenicity of Covid-19 and Influenza combination Vaccine.

  • Phase 2a study to evaluate the efficacy, safety and tolerability of OLP-1002 subcutaneous injections for reducing moderate to severe pain due to Osteoarthritis.

  • Phase 3 study to evaluate the safety and immunogenicity of two booster doses of the NVX-CoV2515 and Bivalent SARS-CoV-2rS vaccines in adults previously vaccinated with other COVID-19 Vaccines.

  • Phase 2 study to evaluate the treatment effect of Pentosan Polysulfate Sodium compared with placebo on synovial fluid biomarkers in participants with knee Osteoarthritis pain.

  • Phase 1 study to evaluate the safety, tolerability and pharmacokinetics of Twice daily Topical BioLexa™ in Adult Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis.

  • Phase 2a Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 Monotherapy in Patients with Gout or Hyperuricemia.

  • Phase 1b first in human and proof of concept study to evaluate the safety, tolerability and efficacy of a topical formulation of ZL-1102 in adults with mild to moderate chronic Plaque Psoriasis.

  • Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and efficacy of subcutaneous doses of OLP-1002 in participants with moderate to severe Osteoarthritis in hip or knee.

  • Phase 1/2a study to evaluate the safety, tolerability and efficacy of SCO-792 in subjects with Type 2 Diabetes and Albuminuria.

  • Prospective observational study of comparative persistence with Prolia and Weekly Alendronate in participants with Osteoporosis.

Co/Sub Investigator

  • Phase 2 Study to Evaluate the Efficacy and Safety of SHR0302 tablets in Adult Patients with Alopecia Areata

  • A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects with Moderate to Severe Atopic Dermatitis

  • Phase 2 study to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications

  • Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Topical AT193 in the Treatment of Patients with Mild to Moderate Hidradenitis Suppurativa

  • Phase 2 randomised, multi-centre, double-blind, placebo controlled, parallel-group comparison study to evaluate safety, tolerability and efficacy of SCO-792 in subjects with Obesity and Type 2 Diabetes Mellitus on Metformin monotherapy.

  • Phase 3 randomized, double-blind, placebo-controlled study to assess the effects of Bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are Statin Intolerant.

  • Phase 2 study to evaluate the safety and efficacy of SHR0302 in adult participants with Alopecia Areata.

  • Phase 3 randomised, double-blind trial to evaluate efficacy and safety of once daily Empagliflozin 10mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction.

  • Phase 2 study to evaluate the safety and efficacy of CBP-201 on moderate to severe Atopic Dermatitis.

  • Phase 1b Study Followed by an Open-Label Extension to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Topical AT193 in the Treatment of Patients with Moderate to Severe Nail Psoriasis

  • Phase 2b Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Hydrogel (A Human VHIL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

  • Phase 1-2 study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of EN002-gel in patients with non-melanoma skin cancer and precancerous lesions

  • Phase 3 study to evaluate Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

  • Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy Of Intralesional FLD-103 in Subjects with Basal Cell Carcinoma (BCC)

  • Phase 1b Study of DR-01 in Adults with Alopecia Areata or Vitiligo

  • Phase 3 study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  • Phase 3 study to evaluate Efficacy and Safety of Povorcitinib in Participants With Prurigo Nodularis

  • Phase 3 study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ–CSU2)

  • Phase 2 Study to Assess the Safety and Efficacy of Topical Zabalafin Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis (CLEAR-AD1)

  • Phase 2 Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo

  • Phase 2, study to assess the safety and efficacy of topical zabalafin hydrogel versus vehicle In the treatment of participants with mild to moderate atopic dermatitis